Association of CYP2D6 and CYP2C19 Metabolizer Status with Switching and Discontinuing Antidepressant Drugs: an Exploratory Study

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2024 May 26

PMID 38797832

Authors

Jurriaan M J L Brouwer

Klaas J Wardenaar

Ilja M Nolte

Edith J Liemburg

Pierre M Bet

Harold Snieder

Hans Mulder

Danielle C Cath

Brenda W J H Penninx

Affiliations

Soon will be listed here.

Abstract

Background: Tailoring antidepressant drugs (AD) to patients' genetic drug-metabolism profile is promising. However, literature regarding associations of ADs' treatment effect and/or side effects with drug metabolizing genes CYP2D6 and CYP2C19 has yielded inconsistent results. Therefore, our aim was to longitudinally investigate associations between CYP2D6 (poor, intermediate, and normal) and CYP2C19 (poor, intermediate, normal, and ultrarapid) metabolizer-status, and switching/discontinuing of ADs. Next, we investigated whether the number of perceived side effects differed between metabolizer statuses.

Methods: Data came from the multi-site naturalistic longitudinal cohort Netherlands Study of Depression and Anxiety (NESDA). We selected depression- and/or anxiety patients, who used AD at some point in the course of the 9 years follow-up period (n = 928). Medication use was followed to assess patterns of AD switching/discontinuation over time. CYP2D6 and CYP2C19 alleles were derived using genome-wide data of the NESDA samples and haplotype data from the PharmGKB database. Logistic regression analyses were conducted to investigate the association of metabolizer status with switching/discontinuing ADs. Mann-Whitney U-tests were conducted to compare the number of patient-perceived side effects between metabolizer statuses.

Results: No significant associations were observed of CYP metabolizer status with switching/discontinuing ADs, nor with the number of perceived side effects.

Conclusions: We found no evidence for associations between CYP metabolizer statuses and switching/discontinuing AD, nor with side effects of ADs, suggesting that metabolizer status only plays a limited role in switching/discontinuing ADs. Additional studies with larger numbers of PM and UM patients are needed to further determine the potential added value of pharmacogenetics to guide pharmacotherapy.

References

Faul F, Erdfelder E, Buchner A, Lang A . Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41(4):1149-60. DOI: 10.3758/BRM.41.4.1149. View

Bousman C, Arandjelovic K, Mancuso S, Eyre H, Dunlop B . Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2018; 20(1):37-47. DOI: 10.2217/pgs-2018-0142. View

Hicks J, Sangkuhl K, Swen J, Ellingrod V, Muller D, Shimoda K . Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2016; 102(1):37-44. PMC: 5478479. DOI: 10.1002/cpt.597. View

Vos C, Ter Hark S, Schellekens A, Spijker J, van der Meij A, Grotenhuis A . Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(5):e2312443. PMC: 10167565. DOI: 10.1001/jamanetworkopen.2023.12443. View

Zastrozhin M, Grishina E, Denisenko N, Skryabin V, Markov D, Savchenko L . Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018; 11:113-119. PMC: 6029588. DOI: 10.2147/PGPM.S160763. View

Howie B, Donnelly P, Marchini J . A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009; 5(6):e1000529. PMC: 2689936. DOI: 10.1371/journal.pgen.1000529. View

Cipriani A, Furukawa T, Salanti G, Chaimani A, Atkinson L, Ogawa Y . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128):1357-1366. PMC: 5889788. DOI: 10.1016/S0140-6736(17)32802-7. View

Funk C, Hart X, Grunder G, Hiemke C, Elsner B, Kreutz R . Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Front Psychiatry. 2022; 13:826138. PMC: 8898907. DOI: 10.3389/fpsyt.2022.826138. View

Grunder G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I . Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry. 2011; 44(6):236-48. DOI: 10.1055/s-0031-1286282. View

10.

Thorn C, Klein T, Altman R . PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol. 2013; 1015:311-20. PMC: 4084821. DOI: 10.1007/978-1-62703-435-7_20. View

11.

Hiemke C, Hartter S . Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000; 85(1):11-28. DOI: 10.1016/s0163-7258(99)00048-0. View

12.

Marchini J, Howie B, Myers S, McVean G, Donnelly P . A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet. 2007; 39(7):906-13. DOI: 10.1038/ng2088. View

13.

Abdullah-Koolmees H, van Keulen A, Nijenhuis M, Deneer V . Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021; 11:595219. PMC: 7868558. DOI: 10.3389/fphar.2020.595219. View

14.

Solomon H, Cates K, Li K . Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?. Psychiatry Res. 2018; 271:604-613. DOI: 10.1016/j.psychres.2018.12.053. View

15.

Glasgow R, Emmons K . How can we increase translation of research into practice? Types of evidence needed. Annu Rev Public Health. 2006; 28:413-33. DOI: 10.1146/annurev.publhealth.28.021406.144145. View

16.

Muller D, Kekin I, Kao A, Brandl E . Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry. 2013; 25(5):554-71. DOI: 10.3109/09540261.2013.838944. View

17.

Swen J, van der Wouden C, Manson L, Abdullah-Koolmees H, Blagec K, Blagus T . A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023; 401(10374):347-356. DOI: 10.1016/S0140-6736(22)01841-4. View

18.

Fabbri C, Tansey K, Perlis R, Hauser J, Henigsberg N, Maier W . Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol. 2018; 28(8):945-954. DOI: 10.1016/j.euroneuro.2018.05.009. View

19.

Penninx B, Eikelenboom M, Giltay E, van Hemert A, Riese H, Schoevers R . Cohort profile of the longitudinal Netherlands Study of Depression and Anxiety (NESDA) on etiology, course and consequences of depressive and anxiety disorders. J Affect Disord. 2021; 287:69-77. DOI: 10.1016/j.jad.2021.03.026. View

20.

. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022; 9(2):137-150. PMC: 8776563. DOI: 10.1016/S2215-0366(21)00395-3. View